[February 19, 2018]

Tasigna (nilotinib; Novartis) Drug Analysis 2018: An Orally Administered BCR-ABL Tyrosine Kinase Inhibitor - ResearchAndMarkets.com

The "Drug analysis: Tasigna" drug pipelines has been added to ResearchAndMarkets.com's offering.

Tasigna (nilotinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor. In Philadelphia chromosome-positive chronic myeloid leukemia, the BCR-ABL protein activates a number of cell cycle-controlling proteins and enzymes, speeding up cell division. The binding of Tasigna to the BCR-ABL protein blocks the signal that leads to the production of leukemic cells.

Novartis will continue to look to Tasigna to make up for Gleevec's (imatinib; Novartis) downturn caused by the entry of geneic imatinib into the chronic myeloid leukemia (CML) market. The second-generation tyrosine kinase inhibitor (TKI) has displayed cytogenetic and molecular response rates superior to those of Gleevec, but is likely to see its use remain primarily in the second-line setting alongside direct competitor Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka).

Key Topics Covered:

List of Figures

Figure 1: Tasigna for CML - SWOT analysis

Figure 2: Drug assessment summary of Tasigna for CML

Figure 3: Drug assessment summary of Tasigna for CML

List of Tables

Table 1: Tasigna drug profile

Table 2: Tasigna pivotal trial data in CML

Table 3: Tasigna late-phase trial data in CML

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/trj9x7/tasigna?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180219005475/en/

[ Back To TMCnet.com's Homepage ]